ArticleGeneral psychiatry2025
Paeoniflorin ameliorates depressive behaviours by modulating microbiota-gut-brain axis functions.
Article in General psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Gut microbiota-targeted interventions for depression in adolescents and young adults: Mechanisms, evidence strength and clinical strategies-A narrative review.General psychiatry · 2026Review
- Paeoniflorin Ameliorates Alcohol-Induced Depression via Modulating the Gut-Brain Axis and Inhibiting the NF-κB/NLRP3 Inflammasome Pathway in Mice.Phytotherapy research : PTR · 2026Article
- Targeting the gut‒kidney axis for lupus nephritis treatment: multimechanism regulatory strategies and evidence from Traditional Chinese medicine.Chinese medicine · 2026Review
- The lung-brain axis mediates the neuroprotective effects of nasally administered L. salivarius and its EV-delivered metabolite in vascular dementia.Journal of neuroinflammation · 2026Article
- Pharmacology-Driven Dissection of Core Component Sets of Xuefu Zhuyu Decoction in Blood Stasis-Related Cardiovascular Diseases.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Microbiota-gut-brain axis pathogenesis and targeted therapeutics in sleep disorders.Frontiers in neurology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractBackground: Major depressive disorder (MDD), characterised by persistent anhedonia and elevated suicide risk, represents a global mental health challenge. Recent studies suggest a link between gut-brain axis dysfunction and depression. The natural compound paeoniflorin demonstrates clinically relevant antidepressant effects, yet its underlying neurobiological mechanisms remain elusive. Aims: This study aims to examine how paeoniflorin alleviates depression-like behaviours in rats subjected to chronic unpredictable mild stress (CUMS) by modulating the function of gut-brain axis, and explore the connections between gut microbiota, metabolites and MDD. Methods: Depression-like behaviours in rats were induced by CUMS, and the antidepressant effect of paeoniflorin was assessed using behavioural tests. The composition and function of the intestinal microbiota were analysed using 16S rRNA sequencing, and metabolomic analysis was performed on serum, hippocampus, jejunum and faecal samples. Enzyme-linked immunosorbent assay and hematoxylin and eosin staining were used to detect the levels of inflammatory factors and cortisol, as well as the infiltration of inflammatory cells in the jejunum of rats after cohousing. Long-term potentiation assays and Golgi staining were used to detect dendritic spine density and synaptic plasticity, respectively. Results: Paeoniflorin significantly alleviated depression-like behaviours and cognitive deficits in CUMS rats. 16S rRNA sequencing revealed that paeoniflorin improved the abundance and diversity of the gut microbiota in CUMS rats. Enrichment of differential metabolites in the brain, intestine, faeces and serum revealed a primary accumulation in the amino acid metabolism pathway. We further observed a correlation between the relative abundance of microbial communities and metabolites. Cohousing experiments verified that microbial metabolites of paeoniflorin can reduce neuroinflammation and improve synaptic plasticity. Conclusions: Disruptions in gut microbiota and its metabolites impair gut-brain interactions. Paeoniflorin's neuroprotective and antidepressant effects are mediated through the modulation of the function of the gut-brain axis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.